NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

(1:20)

What is Neoadjuvant Therapy? | Dana-Farber Cancer Institute

(3:20)

Potential advantages of neoadjuvant immunotherapy for melanoma

(35)

Studies Back Neoadjuvant Strategies for Melanoma

(8:55)

Expert report on neoadjuvant immune checkpoint inhibitors for Melanoma

(4:58)

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

(1:54)

The evolving role of surgery after neoadjuvant immunotherapy in melanoma

(50)

SWOG S1801: Benefits of neoadjuvant immunotherapy for patients with resectable melanoma

(1:40)

Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab

(56)

Neoadjuvant approaches in melanoma

(3:44)

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients

(2:32)

The personalization of neoadjuvant immunotherapy in stage III melanoma

(1:22)

NADINA: promising neoadjuvant immunotherapy strategies for melanoma

(2:58)

Achieving textbook outcomes with neoadjuvant targeted therapy in borderline resectable melanoma

(1:16)

Advancements in Neoadjuvant, presented by Dr. Xinni Song

(28:14)

Emerging Neoadjuvant and Adjuvant Therapies for Locally Advanced Melanoma

(25:45)

Neoadjuvant therapy for melanoma

(2:10)

The role of neoadjuvant immunotherapy in MSI-high gastric cancer

(1:8)

NeoAdjuvant Therapy: The Path Forward in Melanoma

(21:40)

Neoadjuvant Therapy With Immunotherapy for Stage IIIB-D Melanoma

(5:38)